F

Fox Chase Cancer Center | Philadelphia, PA

Research site
(Unclaimed)
Location
333 Cottman Avenue, Philadelphia, Pennsylvania, United States of America
Site insights

Top conditions

Carcinoma (160 trials)

Lung Cancer (104 trials)

Cancer (98 trials)

Non-Small-Cell Lung Carcinoma (87 trials)

Lymphoma (77 trials)

Top treatments

Paclitaxel
Carboplatin
Cisplatin
Pembrolizumab
Bevacizumab
Gemcitabine
Nivolumab
Docetaxel
paclitaxel
cisplatin

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

142 of 1034
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors

This is a Phase 3, open-label, international, multicenter study of CGT9486 in combination with sunitinib. This is a multi-part study that will enroll...

Enrolling
Metastatic Cancer
Advanced Gastrointestinal Stromal Tumors
Drug: CGT9486
Drug: Sunitinib

This is a first-in-human, Phase 1, multicenter, open-label, dose-escalation study to establish the maximum-tolerated dose (MTD) or recommended dosage...

Active, not recruiting
HER2-expressing Cancers
Drug: ZW49

The goal of this clinical trial is to test CPO301, a type of drug called an antibody drug conjugate in adult patients with advanced or metastatic sol...

Enrolling
Cancer, Lung
Cancer
Drug: CPO301

PART 1: The primary objective of this study is to identify the maximum tolerated dose (MTD) of MK-3795, formerly called PT2385 and/or the recommended...

Active, not recruiting
Kidney Cancer
RCC
Drug: Cabozantinib
Drug: Bezlutifan

Evaluate the safety and tolerability of sotorasib in adult subjects with KRAS p.G12C mutant advanced solid tumors.Estimate the maximum tolerated dose...

Active, not recruiting
KRAS p.G12C Mutant Advanced Solid Tumors
Drug: sotorasib
Drug: Anti PD-1/L1

This study will enroll approximately 160 adult participants who have relapsed or refractory (r/r) iNHL to be infused with the study treatment, axicab...

Active, not recruiting
Marginal Zone Lymphoma
Indolent Non-Hodgkin Lymphoma
Biological: axicabtagene ciloleucel
Drug: Fludarabine

Study GO43104 is a Phase III, randomized, open-label, multicenter study of lurbinectedin in combination with atezolizumab compared with atezolizumab...

Active, not recruiting
Small-Cell Lung Cancer
Drug: Etoposide
Drug: Atezolizumab

This is an open-label, multicenter, Phase 1/2 study evaluating the safety and efficacy of CTX110 in subjects with relapsed or refractory B-cell malig...

Active, not recruiting
Adult B Cell ALL
B-cell Lymphoma
Biological: CTX110

This is a multicenter, global, Phase 2, open-label, 2-part, first-line study to investigate the safety, tolerability, and anti-tumor activity of ZW25...

Active, not recruiting
HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
Drug: Leucovorin
Drug: ZW25 (Zanidatamab)

This is a global, multicenter, open-label safety extension study. Participants receiving single-agent trastuzumab emtansine or trastuzumab emtansine...

Enrolling
Neoplasm Metastasis
Drug: Trastuzumab
Drug: Pertuzumab

A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Ropeginterferon alfa-2b-njft (P1101) in Adult Patients with Essen...

Enrolling
Essential Thrombocythemia
Drug: Ropeginterferon alfa-2b-njft (P1101)

This is a First-in-Human Phase I trial of ATG-101 in Patients with Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas.

Enrolling
Advanced Solid Tumor
Mature B-cell Non-Hodgkin Lymphoma
Drug: ATG-101

This is an open-label, multicenter, extension study. Patients who are receiving clinical benefit from atezolizumab monotherapy or atezolizumab in com...

Enrolling
Cancer
Drug: Niraparib
Drug: Pembrolizumab

This is an open label Phase 1b/2 study to evaluate the efficacy and safety of ACR-368 as monotherapy or in combination with ultralow dose gemcitabine...

Enrolling
Endometrial Adenocarcinoma
Urothelial Carcinoma
Drug: ACR-368
Diagnostic Test: OncoSignature

The current study is designed to evaluate the efficacy and safety of AL102 in patients with progressive desmoid tumors.

Active, not recruiting
Desmoid Tumor
Desmoid
Drug: AL102
Other: Placebo

The purpose of this study is to assess the safety and tolerability of ASP9801 and to determine the recommended phase 2 dose (RP2D). The study will al...

Active, not recruiting
Advanced Cancer
Metastatic Cancer
Biological: ASP9801
Combination Product: Pembrolizumab

This is a Phase III, multicenter, randomized, open-label study designed to evaluate the efficacy and safety of atezolizumab given in combination with...

Active, not recruiting
Carcinoma, Renal Cell
Drug: Cabozantinib
Drug: Atezolizumab

The purpose of this study is to assess the safety and tolerability of BMS-986406 administered alone, in combination with nivolumab, or in combination...

Enrolling
Advanced Cancer
Drug: Pemetrexed
Drug: Paclitaxel

This is a multi-center, open-label, randomized, phase 2/3 trial of the bispecific antibody CTX-009 plus paclitaxel versus paclitaxel in patients with...

Enrolling
Biliary Tract Cancer
Gall Bladder Cancer
Drug: CTX-009
Drug: Paclitaxel

The purpose of this study is to evaluate conversion rate to minimal residual disease (MRD) negativity following the addition of daratumumab to lenali...

Active, not recruiting
Multiple Myeloma
Drug: Lenalidomide
Drug: Daratumumab

Trial sponsors

Temple University Health System (TUHS) logo

Temple University Health System (TUHS) (149 trials)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems